Regeneron: FDA Approval for Billion-Dollar Market – Only 4 Injections per Year!
Reading Time: 3 minutes
FDA approves Livsayis as Regeneron's first approved siRNA drug for a rare muscle disease. Four injections per year and lasting effect provide a clear application advantage. GlobalData expects a $13 billion market by 2034. Additional applications are in development. Regeneron Pharmaceuticals (REGN) is entering a new market. On November 18, after US market close, the FDA approved Livsayis (Cemdisiran) for a specific form of generalized myasthenia gravis. In this rare autoimmune disease, the immune system disrupts the connection between nerves...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

